We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Guidance Recommends Immunogenicity Testing for Response to Proteins in Clinical Trials
Guidance Recommends Immunogenicity Testing for Response to Proteins in Clinical Trials
December 4, 2009
Drugmakers submitting NDAs should include data supporting the full validation of assays related to immunogenicity testing to gauge the risk of patients
developing a harmful immune response to therapeutic proteins, a new FDA draft guidance says.